The use of the last generation insulin analogues for the control of diabetes mellitus in real clinical practice


DOI: https://dx.doi.org/10.18565/pharmateca.2022.4.81-86

O.M. Koteshkova (1), O.V. Dukhareva (1), N.A. Demidov (2), M.B. Antsiferov (1)

1) Endocrinological Dispensary of the Moscow Healthcare Department, Moscow, Russia; 2) Hospital in Moskovsky town of the Moscow Healthcare Department, Moscow, Russia
This article discusses the clinical case of managing a patient with type 1 diabetes mellitus, initially treated with multiple injections of first- generation insulin analogues. On this therapy, disease control was unsatisfactory. There were episodes of postprandial hypoglycemia 3 hours after eating. HbA1c level - 8.2%; the patient was 54% of the time in the target glycemic range, 3% of the time - in the hypoglycemic range, and 43% of the time - in the hyperglycemic range. After switching to the last generation insulin analogue (superfast-acting insulin aspart), it was possible to avoid episodes of postprandial hypoglycemia. Subsequently, episodes of nocturnal hypoglycemia occurred, which were managed by switching the patient from two injections of a first-generation basal insulin analogue to one injection of a last-generation basal insulin analogue (degludec). The combined use of the last generation analogues made it possible to achieve normoglycemia without episodes of hypoglycemia (HbA1c - 6.3%, time spent in the target range - 71%, time spent in the hypoglycemic range - 0%).

About the Autors


Corresponding author: Olga M. Koteshkova, Cand. Sci. (Med.), Head of the Department of Education and Treatment of Diabetes, Endocrinological Dispensary of the Moscow Healthcare Department, Moscow, Russia; koala58@mail.ru


Similar Articles


Бионика Медиа